Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer gets U.S. contract for 50 million COVID-19 vaccine doses for kids

Published 10/28/2021, 07:00 AM
Updated 10/28/2021, 10:25 PM
© Reuters. FILE PHOTO: A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/File Photo

© Reuters. FILE PHOTO: A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/File Photo

(Reuters) -Pfizer Inc and BioNTech SE (NASDAQ:BNTX) said on Thursday they expect to deliver 50 million more doses of their COVID-19 vaccine to the U.S. government by April-end, as the country prepares to vaccinate children.

The move comes after a panel of outside advisers to the U.S. Food and Drug Administration voted on Tuesday to recommend its authorization for the vaccine in children aged 5 to 11. The agency's decision on the vaccine for the age group is awaited.

If authorized and subsequently recommended by the U.S. Centers for Disease Control and Prevention's (CDC) advisory panel, the companies said they expect to then begin shipping the vaccine immediately, in 10 microgram pediatric doses, as directed by the U.S. government.

© Reuters. FILE PHOTO: A nurse shows a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine during a vaccination program for minors between the ages of 12 to 17, in San Jose, Costa Rica, October 26, 2021. REUTERS/Mayela Lopez

The U.S. government has so far secured 600 million doses of the vaccine for use within the country and additional 1 billion doses for donation to low- and lower-middle-income countries.

The drugmakers said they expect initial clinical trial data on the vaccine's use in children -- aged 2 to less than 5 years, and 6 months to less than 2 years -- is expected in the fourth quarter this year or early first quarter of 2022.

Latest comments

Doctors are reporting all kinds of problems their vaccinated patients are developing after taking the vaccine. Covid Vaccine Syndrome is about to become a medical reality, which is already an unofficial reality. And that means more profit for the pharma industry. Medical stocks are the way to go now. Injecting children has to be criminalized ASAP.
Also, doctors are reporting the second dose has the effect of taking the major portion of your antibodies out. They are now saying the A30 variant evades antibodies, but its likely the effect of the 2nd dose of the vaccine. Also, vaccines are now being reported to take out natural immunity one had previously gotten after getting covid.
Source please? Who are these so called doctors? Could you please provide links to this data?
The survival rate for children! We're gambling on long haul effects of virus itself vs. a Vax that is unproven long term.
How does Pfizer know before FDA approves for kids? Makes you wonder how Pfizer can make this order without FDA decision. Its starting to feel like Pfizer=FDA are the same company.
What do you expect. Big pharma literally started the opioid crisis in America lol. These companies can do whatever they please!!!!!
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.